422 G.A. Cabral and A. Staab
Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE (1997) Cannabinoid receptors CB1
and CB2: a characterization of expression and adenylate cyclase modulation within the
immune system. Toxicol Appl Pharmacol 142:278–287
Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R (1997) Structural requirements for
binding of anandamide-type compounds to the brain cannabinoid receptor. J Med
Chem 40:659–667
Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T (1997) Cytokine production in
the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha
inhibitor and an effective neuroprotectant. J Neuroimmunol 72:169–177
Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a trans-
fected cell line expressing a peripheral cannabinoid receptor (CB2): identification of
cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989–999
Sidney S, Beck JE, Tekawa IS, Quesenberry CP, Friedman GD (1997) Marijuana use and
mortality. Am J Public Health 87:585–590
Sinha D, Bonner TI, Bhat NR, Matsuda LA (1998) Expression of the CB1 cannabinoid
receptor in macrophage-like cells from brain tissue: immunochemical characterization
by fusion protein antibodies. J Neuroimmunol 82:13–21
Smith MS, Yamamoto Y, Newton C, Friedman H, Klein T (1997) Psychoactive cannabinoids
increase mortality and alter acute phase cytokine responses in mice sublethally infected
with Legionella pneumophila. Proc Soc Exp Biol Med 214:69–75
Smith SH, Harris LS, Uwaydah IM, Munson AE (1978) Structure-activity relationships
of natural and synthetic cannabinoids in suppression of humoral and cell-mediated
immunity. J Pharmacol Exp Ther 207:165–170
Smith SR, Terminelli C, Denhardt G (2000) Effects of cannabinoid receptor agonist and
antagonist ligands on production of inflammatory cytokines and anti-inflammatory
interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293:136–150
Snella E, Pross S, Friedman H (1995) Relationship of aging and cytokines to the im-
munomodulation by delta-9-tetrahydrocannabinol on murine lymphoid cells. Int J Im-
munopharmacol 17:1045–1054
Specter S, Lancz G, Westrich G, Friedman H (1991) Delta-9-tetrahydrocannabinol augments
murine retroviral induced immunosuppression and infection. Int J Immunopharmacol
13:411–417
SrivastavaMD,SrivastavaBI,BrouhardB(1998)Delta-9-tetrahydrocannabinolandcannabid-
iol alter cytokine production by human immune cells. Immunopharmacology 40:179–
185
Stefano GB, Bilfinger TV, Rialas CM, Deutsch DG (2000) 2-Arachidonyl-glycerol stimu-
lates nitric oxide release from human immune and vascular tissues and invertebrate
immunocytes by cannabinoid receptor 1. Pharmacol Res 42:317–322
Stohlman SA, Woodward JG, Frelinger JA (1982) Macrophage antiviral activity: extrinsic
versus intrinsic activity. Infect Immun 36:672–677
Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K, Evans TG
(1993) Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother
27:827–831
Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H,
Waku K (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine
oranandamideisthephysiologicalligandforthecannabinoidCB2receptor.Comparison
of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol
Chem 275:605–612
Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD (2002) Respiratory and immuno-
logic consequences of marijuana smoking. J Clin Pharmacol 42:71S–81S
Tindall B, Cooper DA, Donovan B, Barnes T, Philpot CR, Gold J, Penny R (1988) The Sydney
AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV
seropositive homosexual men. Aust N Z J Med 18:8–15